5 Easy Facts About RSPO1 Protein Described
All enrolled patients who acquired a minimum of a person dose of zosuquidar or placebo for the duration of induction were monitored for your event of adverse events (439 individuals, 219 on zosuquidar and 210 on placebo). The most common adverse functions were being associated with the period of extended and sizeable myelosuppression as is expected